| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide a GCPII mutant (K699S) having Glutamate generation inhibition and β amyloid decomposition activity, and to provide a pharmaceutical composition containing the GCPII mutant (K699S) as an active substance for prevention and treatment of the following diseases. <P>SOLUTION: The GCPII (glutamate carboxypeptidase II) mutant (K699S) simultaneously has both Aβ decomposition activity higher than that of wild type GCPII and the activity for inhibiting the glutamate generation that is not possessed by the wild type GCPII. Therefore, by recognizing that the effect is extremely excellent and the stability is also excellent comparing with the wild type GCPII, the GCPII mutant (K699S) can be effectively used for a preventive or therapeutic agent of a disease selected from the group consisting of an amyloidosis, an Alzheimer disease, a Down's syndrome with the Alzheimer disease, a cerebral stroke, a paralysis, a dementia, a Huntington disease, a Pick's disease, and a Creutzfeldt-Jakob disease. <P>COPYRIGHT: (C)2013,JPO&INPIT |
